Biomind Labs Inc. announced that the U.S. Food and Drug Administration (FDA) has given the Company Investigational New Drug (IND) clearance related to the Company's New Chemical Entity (NCE) Triptax.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.11 USD | 0.00% | 0.00% | +10.00% |
1st Jan change | Capi. | |
---|---|---|
+10.00% | 8.22M | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- BMND.F Stock
- News Biomind Labs Inc.
- Biomind Labs Inc. Announces FDA Investigational New Drug Clearance for its New Chemical Entity Triptax™ Targeting Treatment-Resistant Depression